Study provides first systematic survey of metabolites across tumor types

January 25, 2018, Dana-Farber Cancer Institute

In an advance reminiscent of the earliest maps of genomic mutations in cancer, investigators at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center have completed the first systematic survey of the products of biochemical reactions within cancer and their relation to the progress of the disease. The products, known as metabolites, arise from the myriad chemical reactions that keep cells alive and functioning.

Published online today by the journal Cell Systems, the survey results provide scientists around the world with a curated dataset with which to track in cancer and potentially uncover vulnerabilities that can be targeted by novel therapies. A website accompanying the new report enables researchers to study patterns of variation in levels across multiple types of cancers, explore how these patterns change as cancers progress, and look for connections between metabolites and drug susceptibility.

"Scientists have known for more than 100 years that metabolic changes are important in cancer, but over the last three decades the field has been dominated by discoveries of the genetic and genomic changes that occur in cancer cells," says the study's senior author, Chris Sander, PhD, of Dana-Farber. "In the last five to 10 years, there has been a resurgence of cancer metabolism research - with a focus on the differences in the metabolic functioning of cancer cells vs. normal cells - and in using that knowledge as the basis for new therapies. The drug methotrexate and, more recently, drugs that inhibit enzymes such as glutaminase or isocitrate dehydrogenase, are excellent examples. We think there is more to come."

The revival has been propelled in part by technological advances that enable scientists to identify large numbers of the metabolites present in normal and cancerous cells - much as advances 20 years ago have made it possible to canvas cells for hundreds or thousands of genomic irregularities.

Metabolism is the catchall term for processes that drive every aspect of cell life - consuming energy, growing, dividing, and performing specific functions within the body. It is as basic to the life of as to cancer cells, although their metabolisms can differ in a variety of ways. Much of cell metabolism involves chemical reactions sparked by enzymes. The products of these reactions are metabolites, which themselves can interact to form other metabolites. The assortment of metabolites within a cell is referred to as its metabolome.

For the current study, researchers built a broad dataset of cancer cell metabolites by merging data from 11 studies involving more than 900 tissue samples and seven different cancer types. Their analysis of the data showed that the composition of metabolites in normal tissue is often far different from that in corresponding types of tumor tissue. Across many tumor types, however, the investigators found that several metabolites showed consistent increases or decreases in abundance compared to normal tissue.

The researchers also collected data on the stage and grade of each tumor (measures of tumor progression and aggressiveness). By linking this data to the metabolite data, they found that a small number of metabolites were associated with aggressive tumors in many cancer types. One such metabolite, kynurenine, which was elevated in aggressive tumors regardless of where they originated, is known to help cells evade an attack from the immune system. "Our findings offer the most comprehensive look to date at the differences in metabolic programming between normal and , and across various kinds of cancer," says Ed Reznik, PhD, of Memorial Sloan Kettering, the co-lead author of the study with Augustin Luna, PhD, of Dana-Farber. "We expect the metabolomics dataset will be an important tool as the field of metabolism moves forward."

Explore further: Metabolic profiles essential for personalizing cancer therapy

Related Stories

Metabolic profiles essential for personalizing cancer therapy

February 7, 2012
One way to tackle a tumor is to take aim at the metabolic reactions that fuel their growth. But a report in the February Cell Metabolism shows that one metabolism-targeted cancer therapy will not fit all. That means that ...

Elucidating the role of circulating nutrients that fuel tumor growth

October 19, 2017
Tumors acquire nutrition necessary for generating energy and building blocks for growth and survival from the body of the patient in which they reside.  Although these nutrients are predominantly provided by the circulating ...

Amino acid consumption associated with how fast cancer cells divide

May 24, 2012
For almost a century, researchers have known that cancer cells have peculiar appetites, devouring glucose in ways that normal cells do not. But glucose uptake may tell only part of cancer's metabolic story. Researchers from ...

Testing blood metabolites could help tailor cancer treatment

June 3, 2016
Testing for metabolic changes in the blood could indicate whether a cancer drug is working as designed, a new study reports.

Computer predicts anti-cancer molecules

June 17, 2008
A new computer-based method of analyzing cellular activity has correctly predicted the anti-tumour activity of several molecules. Research published today in BioMed Central's open access journal Molecular Cancer describes ...

Pancreatic cancer cells find unique fuel sources to keep from starving

August 10, 2016
Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 ...

Recommended for you

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...

Researchers identify ways breast cancer avoids immune system detection

December 18, 2018
Recent breakthroughs in immunotherapy are making a huge difference in treating some forms of cancer, especially metastatic cancer. But breast cancer has proven a tricky foe for this new therapy, and an interdisciplinary team ...

Metal chemotherapy drugs boost the impact of immunotherapy in cancer

December 18, 2018
Due to their powerful tumour-killing effect, metal-based chemotherapies are frequently used in cancer treatment. However, it was hitherto assumed that they damaged the immune system, because of their cytotoxic (cell-damaging) ...

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.